Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
167 results about "Vincristine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vincristine is used to treat various types of cancer. It is a cancer chemotherapy drug that is usually used with other chemotherapy drugs to slow or stop cancer cell growth..
Antineoplastic conjugates of transferrin, albumin and polyethylene glycol
Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS-, HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5'-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=-NH2, -OH, -COOH, -O-CO-R-COR*, -NH-CO-R-COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.
Owner:KRATZ FELIX
Uses of Anti-cd40 antibodies
This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.
Owner:XOMA TECH LTD +1
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
InactiveUS6881420B2Improve oral bioavailabilityReduced bioavailabilityBiocideCapsule deliveryWhole bodyCancer cell proliferation
The present invention provides oral dosage forms and compositions for administering antineoplastic agents, such as irinotecan, etoposide, paclitaxel, doxorubicin and vincristine, whose oral effectiveness is limited by pre-systemic and systemic deactivation in the GI tract. Gelling of the gastric retention vehicle composition, and in the case of solid forms concomitant expansion of the composition, retains the antineoplastic drug in the patient's stomach, minimizing pre-systemic and / or systemic deactivation of the drug.
Owner:TEVA PHARM USA INC
Action of ferulic acid on enhancing drug effect of some medicaments and purpose thereof
InactiveCN101721400AOrganic active ingredientsPharmaceutical non-active ingredientsCatharanthineChemical reaction
The invention relates to an action of ferulic acid on enhancing the drug effect of some medicaments and a purpose thereof, wherein the medicaments mainly comprise alkaloid medicaments including matrine, kushenin, sophocarpine, hyoscyamine, narceine, hanfangchin A, jamaicin, morphine, codeine, evodiamine, strychnine, catharanthine, vincristine, taxol, verticine, peimine, peiminine, ephedrine, pseudoephedrine, wilfordine, triptolide, tripdiolide and the like, and flavonoid medicaments including puerarin, ginsenoside, ginsengenin, mangiferin, scutelloside, alkannin, meletin, rutin, hesperidin, daidzin, soybean isoflavone, daidzein, carthamin, catechin and the like. The ferulic acid and the medicaments can form a compound or a medicament compound, or the ferulic acid and the medicaments can generate a chemical reaction (including salification, esterification, amidation, ketonization, etherification and the like), and / or the ferulic acid and the medicaments can generate a synergistic effect and an additive effect.
Owner:QINGDAO QIYUAN BIO TECH CO LTD
Folic acid receptor targeted liposome medicine carrier, its preparation and application
ActiveCN1621092AImprove convenienceImprove stabilityOrganic active ingredientsAntineoplastic agentsFreeze-dryingCholesterol
The present invention discloses one kind of folic acid acceptor targeting liposome as medicine carrier and its preparation process and application. The liposome has components including synthetic phospholipid, cholesterol, folic acid acceptor targeting anchor point and polyglycol hydrating anchor point. The present invention has relatively simple preparation process, and can prepare liposome of size smaller than 200 nm in large scale and prepare freeze dried powder of weak alkali medicine, including leurocristine, etc. carried on the liposome with greatly raised use convenience and stability. The medicine is re-constructed with bacteria-free water or brine before use, and the medicine leakage rate is lower than 10 %.
Owner:ZHEJIANG JIANFENG HANSHENG BIOSCI +1
Process of synthesis of 3',4'-anhydrovinblastine, vinblastine and vincristine
The present invention relates to the synthesis of dimer alkaloid compounds, particularly those of the Catharantus (Vinca) family, from an indole unit, such as cantharanthine, and a dihydroindole unit, such as vindoline. A multi-step process is disclosed including the steps of (1) of 1,4-reduction of a first dimeric iminium intermediate to an enamine compound by reaction with a 1,4-dihydropyridine compound; (2) oxidative transformation of the resulting enamine to a second iminium intermediate under controlled aeration; (3) reduction of the second iminium intermediate to form the target dimer alkaloid compounds. The entire process can be conducted in a one-pot operation to obtain the target compounds without isolation of the intermediates.
Owner:THE UNIV OF BRITISH COLUMBIA
Fgfr1 extracellular domain combination therapies
InactiveUS20120237511A1Inhibit tumor cell growthOrganic active ingredientsHeavy metal active ingredientsCarboplatinDocetaxel
Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and / or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and / or an FGFR1 ECD fusion molecule and / or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and / or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
Owner:FIVE PRIME THERAPEUTICS
Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent
ActiveUS20080274120A1Reduced characteristicsReduced viabilityBiocidePeptide/protein ingredientsVincristineLeukemia
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Owner:TOPOTARGET UK LTD
Nano micelle preparation of Catharanthus roseus alkaloids antineoplastic drugs with coating of phospholipid derived from polyethylene glycol
The invention provides intravenous nanomicelle agents of vinca alkaloids antitumor drug, it contains an effective dose for treating of vinca alkaloids antitumor drug (vinblastine and vincristine or vindesine), macrogol derivatization phospholipid, and the pharmaceutical acceptable adjuvants. Its preparation is to pack the drug in the formative nanomicelle agents, prepare and make the intravenous nanomicelle agents of vinca alkaloids antitumor drug. Vinca alkaloids antitumor drug and macrogol derivatization phospholipid form into a very uniform size nanomicelle. In micelles, polyethylene glycol molecule and hydrophobic core for drug packing form a hydrophilicitious inhibitory coating, avoid the drugs contact with the protein such as enzymes in the blood and identified and phagocytized by the endothelial system in vivo, phagocytosis, the cycle time of micellar in vivo is extended. In addition, the micellar drug also increases the storage stability and the effect on the tumor of the drug and reduces drug toxicity.
Owner:BEIJING DEKERUI MEDICAL TECH
Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin
InactiveUS20080213183A1Organic active ingredientsIn-vivo testing preparationsCisplatinMaximum tolerated dose
The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthermore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination with free or liposomal encapsulated antineoplastic agents, such as idarubicin, irinotecan, etopside, cisplatin, cyclophosphamide, doxorubicin, or vincristine are diclosed.
Owner:BRITISH COLUMBIA CANCER AGENCY
Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
ActiveUS8987262B2Reduce expressionPrevents cardiac hypertrophyBiocideUrea derivatives preparationBeta blockerBETA BLOCKING AGENTS
The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
Owner:UNIV DE BORDEAUX +1
Compositions and methods for treating lymphoma
InactiveUS7244450B2Increase cancerous propertyOrganic active ingredientsLiposomal deliveryMedicineLiposome
This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
Owner:ACROTECH BIOPHARMA LLC +2
Cyclic octapeptide compound in Hsisha sponge and application thereof
InactiveCN101519436AEasy to prepareGood antitumor activityPeptidesCyclic peptide ingredientsPositive controlStructural formula
The invention relates to the technical field of medicaments, which is a novel cyclic octapeptide compound with antineoplastic activity produced from a marine animal Phakellia fusca in the territorial waters near Hsisha Islands. The chemical structural formula of the novel cyclic octapeptide compound is shown as a formula (I), wherein a group R1 is expressed as a formula (II), R2 represents CH (CH3)2or CHCH3(CH2CH3), R3 represents CH2CH (CH3)2, R4 represents CHCH3(CH2CH3)or CHOH (CH3), and R5 represents CHCH3(CH2CH3)or CH2CH (CH3)2. The in vitro activity test proves that the compound has certain inhibiting activity for various tumour cells, wherein the IC50 value of a mouse P388 is only 7.8 mu g / ml and is superior to a positive control medicament vincristine, so the cyclic octapeptide compound can be used for preparing antitumor medicaments. The invention provides a lead compound for developing a novel antitumor medicament.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Quinine drug-vincristine drug co-carried liposome and preparation method thereof
ActiveCN103520159ASmall toxicityWide choiceAntineoplastic agentsLiposomal deliveryCholesterolPhospholipid
The invention discloses a quinine drug-vincristine drug co-carried liposome and a preparation method thereof. The liposome comprises drugs, a phospholipid, a cholesterol compound and an aqueous medium, wherein the mass ratio of the drugs, the phospholipid and the cholesterol compound is 1:(2-100):(1-35), and the drugs comprise a quinine drug and a vincristine drug. With utilization of the synergistic effect of the quinine drug and the vincristine drug, the quinine drug-vincristine drug co-carried liposome has the characteristics of inhibition of multidrug resistance and reduction of medicating toxicity. The preparation method of the co-carried liposome is simple in preparation process, mild in conditions, fewer control parameters, beneficial for reducing the production cost, and easy to industrially produce.
Owner:邱利焱
Liposomes for treatment of multiple myeloma
A method for treating multiple myeloma in newly diagnosed or previously treated patients is described. The method comprises administering a composition consisting of a combination of chemotherapeutic agents of an anthracycline antibiothic, preferably entrapped in a liposome, dexamethasone, and thalidomide, and, optionally, a reduced dose of vincristine.
Owner:ALZA CORP
Cyclic heptapeptide compound in Hsisha sponge and application thereof
InactiveCN101519437AEasy to prepareGood antitumor activityPeptidesCyclic peptide ingredientsPositive controlStructural formula
The invention relates to the technical field of medicaments, which is a novel cyclic heptapeptide compound with antineoplastic activity produced from a marine animal Phakellia fusca in the territorial waters near Hsisha Islands. The chemical structural formula of the novel cyclic heptapeptide compound is shown as the right formula. The in vitro activity test proves that the compound has certain inhibiting activity for various tumour cells, wherein the IC50 value of SPC-A-1 cells is only 31.4 mu g / ml and is superior to a positive control medicament vincristine, so the cyclic heptapeptide compound can be used for preparing antitumor medicaments. The invention provides a lead compound for developing a novel antitumor medicament.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Drug combination useful for prevention of restenosis
ActiveUS8029561B1Good treatment effectLimited degreeStentsOrganic active ingredientsDexamethasoneWhole body
The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the antiinflammatory agent, dexamethasone, to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir.
Owner:WYETH LLC
Application of cyclic dinucleotide cGAMP to treatment of tumors through drug combination
InactiveCN106267213AInhibition of adverse reactions weakenedImprove anti-tumor efficacyOrganic active ingredientsAntineoplastic agentsCarboplatinIn vivo
The invention discloses application of cyclic dinucleotide cGAMP to prevention and treatment of tumors through drug combination, belonging to the technical field of biological medicine. The invention also discloses a plurality of drug compositions for prevention and treatment of tumors. The drug compositions for prevention and treatment of tumors are composed of cyclic dinucleotide and one selected from a group consisting of fluorouracil, cyclophosphamide, methotrexate, cisplatin, carboplatin, paclitaxel, vincristine, mitomycin, gemcitabine and actinomycin. Results of in-vivo research show that the drug compositions composed of cyclic dinucleotide and one selected from a group consisting of fluorouracil, cyclophosphamide, methotrexate, cisplatin, carboplatin, paclitaxel, vincristine, mitomycin, gemcitabine and actinomycin have obviously improved curative effect and obviously decreased toxicity.
Owner:LIAOCHENG CITY ORIENT BIOMEDICAL TECH CO LTD
Cyclic peptide compound in Hsisha sponge and application thereof
InactiveCN101519438AEasy to prepareGood antitumor activityPeptidesCyclic peptide ingredientsCyclic peptidePositive control
The invention relates to the technical field of medicaments, which is a novel cyclic peptide compound with antineoplastic activity produced from a marine animal Phakellia fusca in the territorial waters near Hsisha Islands. The chemical structural formula of the novel cyclic peptide compound is shown as the right formula. The in vitro activity test proves that the compound has certain inhibiting activity for various tumour cells, wherein the IC50 value of BEL-7402 cells is only 29.7 mu g / ml and is obviously superior to a positive control medicament vincristine, so the cyclic peptide compound can be used for preparing antitumor medicaments. The invention provides a lead compound for developing a novel antitumor medicament.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
High-activity anti-caner new medicament formalardeemin for inhibiting multi-drug resistance of tumor cells
The invention relates to indole alkaloid formalardeemin shown in a chemical structural formula ((-)-5-N-formalardeemin), pharmaceutically acceptable salts of the same, and application of the indole alkaloid formalardeemin serving as an anti-tumor medicament in curing malignant tumors of human beings. The indole alkaloid formalardeemin serving as an anti-tumor medicament can not only inhibit the growth of malignant tumors directly, but also can be used as a chemosensitizer when used together with other anti-tumor medicaments such as doxorubicine, vincristine and the like to achieve the effect of effectively killing tumor cells by reversing the multi-drug resistance of the tumor cells. More significantly, compared with the indole alkaloid formalardeemin serving as a tumor cell growth inhibitor directly, the indole alkaloid formalardeemin serving as the chemosensitizer has a better effect, so the indole alkaloid formalardeemin has important clinical application prospect.
Owner:成都常春藤生物科技有限公司
Vincristine-reversal agent composite nano-granule and preparation method and use thereof
InactiveCN101361714AResidue reductionHigh tumor inhibition ratePowder deliveryAntineoplastic agentsMedicineMortality rate
The invention relates to a vincristine-reversion agent compound nano particle, a preparation thereof and applications, belonging to the medicine field. A first technical problem to be solved by the invention is: overcoming the phenomena of multidrug resistance MDR of various tumor cells to the vincristine, namely, the vincristine and the reversion agent are wrapped and carried in a PLGA in a compound way, for preparing the nano particles. With the purposes of obtaining the smaller-diameter nano particles and reducing the vestigital of the surface active agent, F68 and TPGS are adopted as the surface active agent; compared with PVA, the TPGS and the F68 can obviously increase the mortality of drug-resistant breast cancer cells (p is smaller than 0.05); and the tumor-inhibition rate of the TPGS is obviously higher than that of the F68.
Owner:SICHUAN UNIV
Method for promoting terpene indole alkaloid content of Vinca rosea hairly root by transcription factor
InactiveCN1807631AIncrease contentSolve the shortage of medicine resourcesMicrobiological testing/measurementFermentationPcr assayFluorescence
The invention discloses a Vinca rosea trichoid root terpenes indole alkaloid content improving method of transcription factor in the biological domain, which is characterized by the following: cloning str and g10h clone form vinca rosea; gaining trans-gene Vinca rosea trihoid root by genetic conversing Vinca rosea; measuring the alkaloid content of Vinca rosea trichoid root by LC; measuring relative gene expression of biological synthesis of Vinca rosea trichoid root alkaloid by fluorescence quantitative PCRíú The important alkaloid content of trans-gene Vinca rosea trihoid root from the invention gets a distinctive increasing, which provides a new method of producing anti-cancer drugs VLB and LCR for clinic demand.
Owner:SHANGHAI JIAO TONG UNIV
Vincristine nano targeting slow-release long-circulation liposome and preparation method thereof
InactiveCN102225053AHigh drug loading rateEasy and quick to makeOrganic active ingredientsPharmaceutical non-active ingredientsTumor targetCholesterol
The invention relates to a vincristine nano targeting slow-release long-circulation liposome and a preparation method thereof. The uniform particle size of the liposome is in the range of 50-200 nm, and polyethylene glycol and folic acid are rich on the surfaces of the liposome particles. The ratio in parts by mass of raw materials is that folate-conjugated octadecyl-quaternized lysine modified chitosan (FA-OQLCS): PEGlated octadecyl-quaternized lysine modified chitosan (PEG-OQLCS): vincristine=1: (1-2): (0.5-1); the ratio of the total amount of FA-OQLCS and PEG-OQLCS to cholesterol=(4-2):1; the liposome is prepared by a reverse-phase evaporation method or thin-film dispersion method; the entire preparation method is simple and rapid, the preparation period is short, and the drug loading rate of the prepared polymer liposome is up to 9.7%; and the surface polyethylene glycol modification enables the polymer liposome not to be easily caught by a human reticulo-endothelial system and prolongs the circulation time of the polymer liposome, and the folate modification contributes to the tumor targeting property of the polymer liposome.
Owner:TIANJIN UNIV
Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents
This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
Owner:EXELIXIS INC
Compounds and compositions for the treatment of cancer
New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.
Owner:PROMETIC PHARMA SMT LTD
Method for producing vincaleuucoblastine and/or vincristine
InactiveCN101333512AResolving Synthetic InconsistenciesEasy to synthesizeFermentationPlant cellsSucrosePlant cell
The invention discloses a method for producing vinblastine and / or vincristine. The method comprises: inoculating a periwinkle polyploid cell strain in a synthetic medium, and obtaining a cell rich in vinblastine and vincristine by cultivating the strain for 3 to 7 days at the temperature between 20 and 29DEG C; and the synthetic medium is a liquid culture medium obtained by adding 0 to 5mg / L of plant cell auxin, 0 to 5mg / L of plant cytokinin, 30 to 60g / L of sucrose, 1 to 50mu g / L of acetyl coenzyme A, 10 to 40mu g / L of hydogen peroxide, 0.1 to 2mu mol / L of Benzotriazole methl, 10 to 150mg / L of tryptophan, 10 to 110mg / L of loganin and 10 to 50mg / L of cerium chloride in a minimal medium. The method using periwinkle cells to cultivate and produce vinblastine and vincristine can stably realize the industrialized production of vinblastine and vincristine, and the production cost is rather low, the culture period is short, and the production is insusceptible to the natural environment and weather, so the year-round production can be realized.
Owner:TSINGHUA UNIV
Compositions and methods for treating lymphoma
InactiveUS20090028933A1Increase cancerous propertyOrganic active ingredientsBiocideDexamethasoneOncology
The present invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of leukemias, including acute lymphoblastic leukemia (ALL). These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, in combination with dexamethasone to a mammal with a leukemia.
Owner:TALON THERAPEUTICS
Drug Combinations Useful for Prevention of Restenosis
InactiveUS20120029475A1Limited degreeEnhance restenosis-limiting actionStentsOrganic active ingredientsRestenosisDexamethasone
Owner:KOPIA GREGORY A +2
Senolytic compounds
PendingCN110678187AHalogenated hydrocarbon active ingredientsCyclic peptide ingredientsDiseaseNitrofurazone
The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein the agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-CoA reductase inhibitor, JFD00244, Cyclosporine, Tyrphostin AG879, Cantharidin, Diphenyleneiodonium chloride, Rottlerin, 2,3-Dimethoxy-1,4-naphthoquinone, LY-367,265,Rotenone, Idarubicin, Dequalintum chloride, Vincristine, Nitazoxanide, Nitrofurazone, Temsirolimus, Eltrombopag, Adapalene, Azacyclonol, Enoxacin and Raltegravir, and pharmaceutically acceptable salts thereof. Another aspect relates to compounds for use in treating or preventing a senescence- associated disease or disorder, and methods relating thereto.
Owner:英国研究与创新公司
Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
Owner:TOPOTARGET UK LTD
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com